A Phase 1 interventional study of AZD2171 and AZD0530 in Neoplasms, sponsored by AstraZeneca. Completed at 3 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-04-15.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
The purpose of the study is to determine if the maximum tolerated doses of AZD2171, in combination with AZD0530, in treating patients with advanced solid tumours are safe, tolerable and efficacious.
9,610 studies on the registry are indexed under Neoplasms; 2,508 are open to participants now.
This study's enrollment of 40 is below the median of 50 across 7,429 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →AstraZeneca is the lead sponsor of 3,492 studies on the registry; 266 are open to participants now.
Of its 368 completed or terminated interventional studies of FDA-regulated products, 176 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
AZD2171 Monotherapy
Drug: AZD2171
AZD2171 + AZD0530
Drug: AZD2171 · Drug: AZD0530
Determine the safety and tolerability of ascending daily oral doses of AZD2171 when co-administered with AZD0530 to patients with advanced solid tumours by assessment of AEs, vital signs, HRCT Scans, clin chem, haematology, urinalysis, ECG and phys exam
Time frame: assessed at each visit
Pharmacokinetics (PK) of AZD2171 alone and in combination with AZD0530
Time frame: assessed at each visit
Safety and efficacy
Time frame: assessed at each visit
Genetic variation of pathways targeted by AZD2171 and AZD0530
Time frame: assessed during study
The record gives a start of May 2007, a primary completion of Oct 2008 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Saracatinib